Co-Diagnostics, Inc., based in Salt Lake City, Utah, specializes in developing molecular diagnostics for detecting infectious diseases, cancer screening, and agricultural uses, and went public in 2017. The company designs and distributes reagents and equipment, including a developing portable PCR device, for simplified molecular testing in various settings.
CoDiagnostics (CODX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, CoDiagnostics's actual EPS was -$0.14, beating the estimate of -$0.35 per share, resulting in a 59.63% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
